STERIS (NYSE:STE) Releases FY 2025 Earnings Guidance

STERIS (NYSE:STE) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 9.050-9.250 for the period, compared to the consensus earnings per share estimate of 9.140. The company issued revenue guidance of $5.5 billion-$5.5 billion, compared to the consensus revenue estimate of $5.5 billion. STERIS also updated its FY25 guidance to $9.05-$9.25 EPS.

Analyst Ratings Changes

Several brokerages have recently commented on STE. Piper Sandler reiterated a neutral rating and issued a $225.00 target price (up previously from $220.00) on shares of STERIS in a report on Friday, May 10th. Stephens reiterated an overweight rating and issued a $260.00 price objective on shares of STERIS in a research note on Wednesday. JMP Securities restated a market outperform rating and issued a $265.00 target price on shares of STERIS in a research note on Wednesday. Needham & Company LLC reaffirmed a hold rating on shares of STERIS in a research report on Thursday. Finally, StockNews.com cut STERIS from a buy rating to a hold rating in a research report on Monday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and an average price target of $243.60.

STERIS Stock Performance

Shares of STE traded up $6.24 during mid-day trading on Thursday, hitting $239.77. The stock had a trading volume of 396,771 shares, compared to its average volume of 489,162. STERIS has a 52 week low of $195.47 and a 52 week high of $243.37. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.08 and a quick ratio of 2.36. The business has a fifty day moving average price of $224.84 and a 200-day moving average price of $222.77. The firm has a market cap of $23.70 billion, a P/E ratio of 62.77 and a beta of 0.83.

STERIS (NYSE:STE) last issued its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the business earned $2.00 earnings per share. The company’s quarterly revenue was down .4% on a year-over-year basis. On average, equities research analysts expect that STERIS will post 9.16 EPS for the current year.

STERIS Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 20th. Stockholders of record on Thursday, September 5th will be issued a $0.57 dividend. This is a positive change from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date is Thursday, September 5th. STERIS’s dividend payout ratio (DPR) is presently 59.69%.

Insider Activity at STERIS

In other news, Director Jacqueline B. Kosecoff sold 4,584 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $231.53, for a total value of $1,061,333.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Renato Tamaro sold 1,154 shares of STERIS stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $231.64, for a total transaction of $267,312.56. Following the completion of the sale, the vice president now owns 6,677 shares in the company, valued at approximately $1,546,660.28. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jacqueline B. Kosecoff sold 4,584 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $231.53, for a total transaction of $1,061,333.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,762 shares of company stock worth $1,798,477. 1.14% of the stock is owned by company insiders.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.